Comparative Pharmacology
Head-to-head clinical analysis: NEXPLANON versus XULANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXPLANON versus XULANE.
NEXPLANON vs XULANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
Ethinyl estradiol and norelgestromin (the active metabolites of norgestimate) suppress gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity, impairing sperm penetration.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
Apply 1 patch (20 cm² containing 600 mcg ethinyl estradiol and 6 mg norelgestromin) transdermally once weekly for 3 weeks, followed by 1 patch-free week.
None Documented
None Documented
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Terminal elimination half-life is 4.5 hours; in severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 12-15 hours, requiring dose adjustment.
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Primarily renal (approximately 60-70% as unchanged drug), with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Contraceptive
Contraceptive